Our treatments

This section gives you direct access to resources related to Takeda’s ADHD treatment portfolio, including detailed product information, clinical evidence, and supporting resources.
Whether you're looking to understand treatment options, explore patient support materials, or access the latest updates, everything is designed to help you make informed decisions in your ADHD practice.

Treatments

Elvanse (lisdexamfetamine dimesylate) BMJ website

Explore the Elvanse Hub on BMJ

This dedicated page, hosted by BMJ and developed in partnership with Takeda, brings together expert-led content to support your understanding of adult ADHD and the role of Elvanse in clinical practice.
Access practical resources, real-world insights, and educational materials designed to help you make confident, informed treatment decisions.

Visit

Takeda ADHD portfolio for children and young people

Explore Takeda’s ADHD Portfolio for Children and Young People

This dedicated site brings together key information on Takeda’s licensed ADHD treatments for children and adolescents—Elvanse® (lisdexamfetamine), Intuniv®▼ (guanfacine hydrochloride), and Equasym® XL (methylphenidate).
Designed for UK healthcare professionals, the site offers clinical guidance, prescribing information, and practical resources to support confident treatment decisions across a range of patient needs.
Whether you're looking to tailor therapy by mode of action, duration, or tolerability, this platform helps you navigate options and optimise care for young people living with ADHD.

Visit

Treatment categories

Initiation checklists

Elvanse® (lisdexamfetamine dimesylate) initiation checklist

This checklist supports UK healthcare professionals in initiating Elvanse for ADHD, detailing contraindications, monitoring requirements, comorbidities, drug interactions, and patient history considerations.

PDF

Intuniv®▼ (guanfacine hydrochloride) ABC initiation checklist

This initiation checklist outlines baseline assessments, dosing schedules, and monitoring requirements for starting patients aged 6–17 on INTUNIV for ADHD, including cardiovascular, psychological, and weight-related evaluations.

PDF

Patient product booklets

Patient product booklet – ELVANSE® (lisdexamfetamine dimesylate) and you

This booklet can be given to patients who have been prescribed ELVANSE® (lisdexamfetamine dimesylate).

PDF

Patient product booklet – INTUNIV®▼ (guanfacine hydrochloride) and your child

This booklet can be given to the parents/carers of children who have been prescribed INTUNIV® (guanfacine hydrochloride).

PDF

Patient product booklet – EQUASYM XL® (methylphenidate hydrochloride) and your child

This booklet can be given to the parents/carers of children who have been prescribed EQUASYM XL® (methylphenidate hydrochloride).

PDF

Product videos

INTUNIV®▼ (guanfacine hydrochloride) Mode of Action

This video explains the proposed mechanism of action of INTUNIV®▼ (guanfacine hydrochloride) in the treatment of ADHD.

Video

5 minutes 6 seconds

Prodrug technology

This video describes the unique prodrug technology of Elvanse (lisdexamfetamine dimesylate), explaining its unique delivery mechanism, conversion process in red blood cells, and factors affecting its bioavailability.

Video

1 minutes 32 seconds

Elvanse (lisdexamfetamine dimesylate) Mode of Action video

This video explains the proposed mechanism of action of Elvanse (lisdexamfetamine dimesylate) in the treatment of ADHD.

Video

1 minutes 30 seconds

C-APROM/GB/NS/1232 | September 2025